Transfer of care between healthcare providers and between teams can pose risk to patient safety, particularly where medicines are concerned. The GMC good practice guidance regarding information sharing with colleagues involved in patient care reminds prescribers:
You must contribute to the safe transfer of patients between healthcare providers and between health and social care providers. This means you must share all relevant information with colleagues involved in your patient’s care within and outside the team, including when you hand over care as you go off duty, when you delegate care or refer patients to other health or social care providers. This should include all relevant information about their current and recent use of other medicines, other conditions, allergies and previous adverse reactions to medicines.
22 July 2016
Sacubitril valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:
with New York Heart Association (NYHA) class II to IV symptoms and
with a left ventricular ejection fraction of 35% or less and
who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor-blockers (ARBs).
The attached briefing is designed to inform CCGs of the implications of NICE TAG 388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction.
1 July 2016
The MHRA have issued a Medical Device Alert regarding home use of blood glucose monitoring system: TRUEyou blood glucose test strips and the risk of false low blood glucose results. Certain lots of test strips may give incorrect low blood glucose results that could lead to undetected hyperglycaemia.